Lung cancer combo trial halted early: what we know
NCT ID NCT04748419
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study aimed to see if adding a special type of radiation therapy to the immunotherapy drug durvalumab could better control stage III lung cancer after standard treatment. Only 6 people took part before the study was stopped. The goal was to check safety and see if the combination improved tumor control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can a new PET tracer light up hidden cancers?